Endara, P; Vaca, M; Chico, ME; Erazo, S; Oviedo, G; Quinzo, I; Rodriguez, A; Lovato, R; Moncayo, AL; Barreto, ML; Rodrigues, LC; Cooper, PJ (2010) Long-term periodic anthelmintic treatments are associated with increased allergen skin reactivity. Clinical and experimental allergy, 40 (11). pp. 1669-77. ISSN 0954-7894 DOI: https://doi.org/10.1111/j.1365-2222.2010.03559.x

Downloaded from: http://researchonline.lshtm.ac.uk/2192/

DOI: 10.1111/j.1365-2222.2010.03559.x

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Long-term periodic anthelmintic treatments are associated with increased allergen skin reactivity

P. Endara¹, M. Vaca¹, M. E. Chico¹, S. Erazo¹, G. Oviedo¹, I. Quinzo¹, A. Rodriguez¹,², R. Lovato², A.-L. Moncayo¹,², M. L. Barreto², L. C. Rodrigues⁴ and P. J. Cooper¹,⁵

¹Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador, ²Instituto de Saude Coletiva, Universidade Federal de Bahia, Salvador, Brazil, ³Programa Nacional de Eliminacion de Oncocercosis, Ministerio de Salud Publica, Guayaquil, Ecuador, ⁴Department of Epidemiology, London School of Hygiene and Tropical Medicine, London, UK, and ⁵Center for Infection, St George’s University of London, London, UK

Summary

Background The low prevalence of allergic disease in the rural tropics has been attributed to the protective effects of chronic helminth infections. There is concern that treatment-based control programmes for these parasites may lead to an increase in the prevalence of allergic diseases.

Objective We measured the impact of 15–17 years of anthelmintic treatment with ivermectin on the prevalence of allergen skin test reactivity and allergic symptoms in school-age children.

Methods The prevalence of allergen skin test reactivity, exercise-induced bronchospasm and allergic symptoms was compared between school-age children living in communities that had received community-based treatments with ivermectin (for onchocerciasis control) for a period of 15–17 years with those living in geographically adjacent communities that had received no ivermectin.

Results The prevalence of allergen skin test reactivity was double in children living in treated communities compared with those in untreated communities (16.7% vs. 8.7%, adjusted OR 2.10, 95% CI 1.50–2.94, \(P\) < 0.0001), and the effect was mediated partly by a reduced prevalence of Trichuris trichiura among treated children. Ivermectin treatments were associated with an increased prevalence of recent eczema symptoms (adjusted OR 2.24, 95% CI 1.05–4.78, \(P\) = 0.04) but not symptoms of asthma or rhino-conjunctivitis. The effect on eczema symptoms was not associated with reductions in geohelminth infections.

Conclusion Long-term periodic treatments with ivermectin were associated with an increased prevalence of allergen skin test reactivity. There was some evidence that treatment was associated with an increased prevalence of recent eczema symptoms but not those of asthma or rhino-conjunctivitis.

Keywords allergen skin reactivity, geohelminths, ivermectin

Submitted 23 December 2009; revised 5 April 2010; accepted 7 May 2010

Introduction

The prevalence of allergic diseases appears to be low in rural areas of developing countries [1, 2]. In such areas, poverty and the inadequate disposal of faeces are commonplace and there is a high prevalence of geohelminth infections [3]. Geohelminth parasites are estimated to infect 3.8 billion humans world-wide [4], and WHO has endorsed the control of these infections through the provision of periodic treatments with anthelmintic drugs to high-risk groups particularly schoolchildren [4].

Several epidemiologic studies have provided evidence for an inverse association between geohelminth infections and allergen skin test reactivity in areas where these infections are highly endemic [5–8] and it has been suggested that geohelminths may suppress allergy in these populations [6, 9]. This has raised the concern that the mass treatment of helminth infections through anthelmintic treatment programmes may increase the
prevalence of allergic disease in populations where these infections are endemic.

Intervention studies of periodic anthelmintic treatment have provided conflicting evidence with three studies showing an increased risk of allergen skin test reactivity after treatment [10–12] and one study showing no effect on allergen skin test reactivity or allergic disease [13]. The negative study provided treatment for 12 months while the other three studies with positive findings provided treatment for between 12 and 30 months.

An opportunity to study the long-term effects of anthelmintic treatment on allergy was provided by a control programme for onchocerciasis that has been treating endemic communities with the broad-spectrum anthelmintic drug ivermectin at annual or semi-annual intervals for the past 15–17 years [14]. Because ivermectin also has potent activity against geohelminths [15], we investigated the impact of long-term ivermectin treatments on allergen skin test reactivity and allergic disease by comparing the prevalence of these parameters in children living in communities that had received mass treatments with ivermectin with children living in geographically adjacent communities that had never received ivermectin treatments.

Methods

Study population and design

The study was conducted between March 2005 and April 2007 in the Districts of Eloy Alfaro and San Lorenzo in the northern coastal Province of Esmeraldas, Ecuador [16]. Most communities were located along rivers in a tropical rain forest area at altitudes below 100 m above sea level. Greater than 90% of the population in each study community was Afro-Ecuadorian. The main economic activities are agriculture, logging, fishing and the extraction of African Palm oil. Poorly developed infrastructure, untreated sewage and rudimentary solid waste disposal are common characteristics of most communities. All children aged 6–16 years in the communities were eligible to participate. Updated censuses from all communities were used as the basis for recruitment. Informed written consent was obtained from the child’s parents or guardian. The study protocol was approved by the Ethics Committee of the Hospital Pedro Vicente Maldonado, Ecuador.

Selection of communities

Treated communities were selected according to the treatment schedule of the Ecuadorian Onchocerciasis Elimination Programme (EOEP). Non-treated communities were selected from maps of the study area and consisted of geographically adjacent communities selected to be as similar as possible with respect to size, ethnicity, and socio-economic characteristics. *Onchocerca volvulus* infection was never present in non-treated communities and none have received mass ivermectin treatment. The prevalence of *O. volvulus* infection in treated communities before the introduction of ivermectin was >40% in adults but lower in children [17]. No other filarial helminth infections were present in the study area [18].

Ivermectin treatment

Twice-annual community treatments with ivermectin were initiated between 1991 and 1992. The second annual dose was suspended in 1995–1996 and then reintroduced from 1998. Eligibility criteria for treatment are: weight >15 kg and free of serious illness (e.g. active tuberculosis, terminal cancer, etc.), and for women, not pregnant and not nursing infants up to 3 months of age. Distribution was organized by community health workers and single-dose treatments of 150 μg/kg ivermectin were observed directly. The annual treatment coverage of the programme was 85.2% (range 54.9–97.9%) over the 15-year period [14].

Subject evaluations

A questionnaire modified from the ISAAC Phase II questionnaire [16] was administered to the child’s mother or guardian to collect information on allergic symptoms and other relevant data. A stool sample was collected and analysed for the presence of eggs and larvae by the modified Kato–Katz and formol-ethyl acetate concentration methods [19]. Skin reactivity was tested to house dust mite (HDM) (*Dermatophagoides pteronyssinus*; Greer Laboratories, Lenoir, NC, USA), grass pollen mix (Greer Laboratories), American cockroach (*Periplaneta americana*; Greer Laboratories), fungi mix (Greer Laboratories), *Alternaria tenuis* (Greer Laboratories), cat (Greer Laboratories) and dog (Greer Laboratories) extracts. Allergens and positive histamine and negative saline controls were pricked onto the volar surface of the forearm, and reactions were recorded after 15 min. A reaction was considered positive if the mean diameter was ≥3 mm greater than the negative control. All tests were conducted by the same observer (M. V.). Exercise-induced bronchospasm (EIB) was performed in a subgroup of 2040 children, 437 (21.4%) from non-treated and 1603 children (78.6%) from treated communities. Peak expiratory flow rate (PEFR) was measured before and after 6 min of vigorous exercise as described previously [13].

Statistical analysis

Allergen skin test reactivity was defined as a positive skin test reaction to any allergen. Recent wheeze was classified as wheeze within the previous 12 months; recent rhino-
conjunctivitis as the presence of rhinitis symptoms accompanied by itchy eyes within the previous 12 months; recent eczema symptoms as the presence of an itchy skin condition affecting the flexures within the previous 12 months; and EIB as a 15% or greater fall in PEFR after exercise. Analyses were performed using multiple logistic regression models allowing for clustering using robust standard errors. Age, sex, monthly household income, maternal educational level and water source were included as a priori confounders in all models. Other potential confounders were included in the final model if inclusion altered OR by > 10%. Interactions were assessed using the Wald test. Because all children in the treated communities had received at least one dose of ivermectin, we could not do a separate analysis of the effects of treatment in the treated communities. Analyses were performed using StATA 10 (StataCorp, College Station, TX, USA).

Results

Study population

A total of 3901 children were assessed, 2070 children from 27 non-treated and 1831 children from 31 treated communities. The mean cluster size was 76.7 (range 17–224) and 59.1 (range 14–223) in non-treated and treated communities, respectively. Results of allergen skin prick tests were available for 1983 (95.8%) and 1782 (97.4%) from non-treated and treated children and stool samples were collected from 1953 (94.3%) and 1794 (97.8%) of non-treated and treated children, respectively.

Demographic, socio-economic and environmental characteristics of the study children are shown in Table 1 and show differences between treated and non-treated children with respect to several characteristics.

EOEP has achieved extremely high rates of coverage with ivermectin in the study communities over the past 15–17 years [15]. All children living in treated communities had received at least one dose of ivermectin and 79.3% had received > 75% of designated treatments over the previous 5 years. Reported treatments with other anthelmintic drugs by parental questionnaire were similar between treated and non-treated children (Table 2). Children living in treated communities had a higher prevalence of recent eczema symptoms than non-treated children (adjusted OR 2.24, 95% CI 1.05–4.78, \(P = 0.04\)). The prevalence of SPT+ was greater in 11 of 31 treated communities than in any of the non-treated community (Fig. 1), but no patterns were observed for the other allergic parameters (data not shown).

Effect of geohelminth prevalence on the association between treatment area and SPT+

The effect of treatment on SPT+ was explored in hierarchical analyses by examining whether the association between treatment and SPT+ might be explained by reductions in geohelminth prevalence. To investigate this, the effect on the association between treatment area and SPT+ of inclusion of each of A. lumbricoides, T. trichiura and hookworm was assessed either separately or simultaneously in the model. A reduction in OR will occur if the geohelminth is a mediating factor in the causal pathway between treatment and skin test reactivity. The only helminth that reduced the OR between treatment area and SPT+ was T. trichiura (change of OR from 2.10 to 1.69) (Table 3). A. lumbricoides and hookworm had negligible effects. Sequential addition of geohelminths to the model showed a strong effect only when T. trichiura was included in the model (Table 3). A similar analysis for the association between treatment area and eczema symptoms did not show effects for any of the geohelminth parasites (Table 3).

Geohelminth infections and allergic parameters

SPT+. Infection with any geohelminth was significantly inversely associated with SPT+ (OR 0.71, 95% CI
This effect appeared to be explained by a strong inverse association between skin test reactivity and *T. trichiura* infection (OR 0.72, 95% CI 0.58–0.90, *P* = 0.01) – neither *A. lumbricoides* nor hookworm infections were significantly inversely associated with SPT+.

There was evidence for an inverse association between skin test reactivity and *Ascaris lumbricoides* infection (OR 0.72, 95% CI 0.58–0.90, *P* = 0.01).
T. trichiura infection intensity and the prevalence of SPT: OR 0.75 (95% CI 0.60–0.93, P = 0.01) for light infections and OR 0.50 (95% CI 0.35–0.70, P < 0.0001) for the moderate to heavy intensity infections, compared with non-infected children (Table 4).

Wheeze, rhino-conjunctivitis, eczema symptoms and EIB. The prevalence and intensities of A. lumbricoides, T. trichiura and hookworm infections were not associated with symptoms of recent wheeze, rhino-conjunctivitis and eczema or with EIB.

SPT+ and allergic symptoms

There were weak non-significant associations between SPT+ and recent wheeze (adjusted OR 1.29, 95% CI 0.96–1.74, P = 0.09), EIB (adjusted OR 1.32, 95% CI 0.84–2.08, P = 0.23), and recent eczema symptoms (adjusted OR 1.35, 95% CI 0.87–2.12, P = 0.18), but no association with recent rhino-conjunctivitis (adjusted OR 0.97, 95% CI 0.65–1.43, P = 0.87). Treatment did not modify these effects.

Discussion

The present study examined the effect of long-term periodic treatments with a broad-spectrum anthelmintic drug, ivermectin, on the prevalence of allergy in school-age children living in communities in a rural tropical area of Ecuador. To perform this, we compared the prevalence of allergen skin test reactivity and other parameters of clinical allergy between children who lived in communities that had received ivermectin annually or semi-annually for a period of 15–17 years with children living in communities that had never received ivermectin treatment. The data provide evidence that long-term anthelmintic treatment may be accompanied by an increase in the prevalence of allergen skin test reactivity and perhaps recent eczema symptoms but no evidence for effects on asthma or rhinitis symptoms.

Strengths of the study are the objective documentation of allergen skin test reactivity, exercise-induced bronchospasm, and geohelminth infections using standardized protocols. Because the study was conducted over a 2-year period, seasonal differences (i.e. dry vs. rainy season) in rates of skin sensitization could have biased the findings; however, an analysis of skin test reactivity by month showed no evidence for seasonal differences in allergen skin test reactivity (data not shown). A high proportion of
children living in untreated communities had received other anthelmintic treatments during the previous 6 months – these treatments were generally purchased directly by parents from pharmacies and such treatments were not associated with any of the study outcomes (data not shown). We have shown previously that such sporadic and short-term treatments are not associated with SPT [6]. Treatment contamination of the untreated communities, if such treatment were to mediate an effect, would be expected to increase the prevalence of SPT in untreated communities and reduce the estimate of effect. Definitions of clinical allergy including eczema were questionnaire based and used standardized definitions [16]. Questionnaire data could have been associated with possible biases – observation bias because treatment allocation was not concealed and recall bias because the educational levels of the primary respondents to the questionnaires, the mothers, differed by treatment group. Several environmental and socio-economic factors differed between the treated and untreated communities. Although we controlled for these differences by treatment area in the analysis, residual confounding or systematic bias cannot be excluded. However, ORs were stable with respect to controlling for confounding suggesting that these estimates may not be subject to significant confounding.

Table 3. Effects of individual or sequential adjustments for geohelminth infections on the associations between treatment and allergen skin test reactivity or eczema symptoms

| Individually added to the model | Adjusted OR (of treatment area on atopy) = 2.10 (1.50–2.94) P < 0.0001 | Sequentially added to the model |
|--------------------------------|--------------------------------------------------------------------------------|-------------------------------|
| Adjusted OR                    | P-value                                                                 | Adjusted OR                  | P-value          |
| Ascaris lumbricoides           | 2.03 (1.46–2.82) < 0.0001                                                   | A. lumbricoides              | 2.03 (1.46–2.82) < 0.0001 |
| Trichuris trichuria            | 1.69 (1.21–2.37) < 0.02                                                     | Add T. trichuria             | 1.59 (1.15–2.20) < 0.005 |
| Hookworm                       | 2.12 (1.50–2.99) < 0.0001                                                   | Add hookworm                 | 1.57 (1.13–2.19) 0.007 |

Adjusted OR (of treatment area on eczema symptoms) = 2.24 (1.05–4.78) P < 0.04

Ascaris lumbricoides           | 2.30 (1.09–4.86) 0.03                                                      |
| T. trichuria                   | 2.36 (1.11–5.04) 0.03                                                      |
| Hookworm                       | 2.29 (1.08–4.86) 0.03                                                      |

Table 4. Association between allergen skin test reactivity (SPT) and geohelminth infections

| N         | SPT (%) | Crude OR | P-value | Adjusted OR | P-value |
|-----------|---------|----------|---------|-------------|---------|
| Ascaris lumbricoides*           |         |          |         |             |         |
| Negative  | 1713    | 242 (14.1)| 1       | 1           | 1       |
| Positive  | 1950    | 220 (11.3)| 0.77 (0.59–1.0) | 0.06 | 0.87 (0.67–1.12) | 0.27 |
| Intensity (epg)                   |         |          |         |             |         |
| Negative  | 2095    | 300 (14.3)| 1       | 1           | 1       |
| Light (1–4999 epg)                | 807     | 86 (10.7) | 0.71 (0.53–0.96) | 0.03 | 0.77 (0.58–1.02) | 0.07 |
| Moderate (5000–49 999 epg)        | 654     | 64 (9.8)  | 0.65 (0.43–0.97) | 0.04 | 0.70 (0.49–1.0) | 0.05 |
| Heavy (>50 000 epg)               | 107     | 12 (11.2) | 0.76 (0.44–1.29) | 0.31 | 0.85 (0.47–1.55) | 0.60 |
| Trichuris trichiura*             |         |          |         |             |         |
| Negative  | 1562    | 260 (16.7)| 1       | 1           | 1       |
| Positive  | 2101    | 202 (9.6) | 0.53 (0.43–0.67) | < 0.0001 | 0.72 (0.58–0.90) | 0.01 |
| Intensity (epg)                   |         |          |         |             |         |
| Negative  | 1730    | 284 (16.4)| 1       | 1           | 1       |
| Light (1–999 epg)                 | 1313    | 139 (10.6)| 0.60 (0.47–0.77) | < 0.0001 | 0.75 (0.60–0.93) | 0.01 |
| Moderate-heavy (>1000 epg)        | 620     | 39 (6.3)  | 0.34 (0.24–0.49) | < 0.0001 | 0.50 (0.35–0.70) | < 0.0001 |
| Hookworm*                         |         |          |         |             |         |
| Negative  | 3332    | 415 (12.5)| 1       | 1           | 1       |
| Positive  | 331     | 47 (14.2) | 1.16 (0.75–1.80) | 0.5 | 0.94 (0.59–1.48) | 0.77 |
| Any geohelminth                   |         |          |         |             |         |
| Negative  | 919     | 158 (17.2)| 1       | 1           | 1       |
| Positive  | 2744    | 304 (11.1)| 0.60 (0.46–0.78) | < 0.0001 | 0.71 (0.55–0.91) | 0.007 |

*ORs for A. lumbricoides, T. trichiura, and hookworm were adjusted for the presence of the other two parasites. OR for hookworm is adjusted also for number of electrical appliances.

All ORs are adjusted for treatment area, age, sex, income, maternal educational level, water source.

© 2010 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 40: 1669–1677
An important potential limitation of the present study was the absence of data from two decades previously on the prevalence of SPT and allergic outcomes in the communities before the start of ivermectin distribution. We believe that the prevalence of these outcomes was unlikely to have been systematically different between these Afro-Ecuadorian communities because 20 years ago, these communities were more homogeneous than they are now given the geographic isolation of the study area, a similar tropical rain forest environment, and a shared lifestyle and ethnicity reinforced by contact between communities by river. Only more recently have differences started to emerge (see Table 1) caused by the building of roads and social and environmental changes associated with the process of modernization [20] that so far have started to intrude upon untreated more than treated communities. The differences between treated and untreated communities observed in Table 1 (e.g. maternal educational level, number of household electrical appliances and sources of drinking water) indicate a greater degree of ‘rurality’ in treated communities, a factor that is considered to be strongly protective against atopy [21]. Such a bias would be expected to reduce rather than increase the prevalence of SPT among children living in treated compared with untreated communities. The findings that SPT and eczema had a higher prevalence in the treated communities but asthma prevalence was similar between treated and non-treated communities are consistent with previous intervention studies: an elevated prevalence of SPT [10, 12] and eczema [22] in treated arms but similar prevalence of asthma in children living in treated and non-treated arms [12, 13].

Epidemiological studies have shown strong inverse associations between SPT+ and geohelminth infections in high-prevalence populations [5–8], and the inverse associations observed in the present studies are similar to those reported in previous studies conducted in rural Ecuador [6, 13, 23]. The inverse associations have been interpreted to indicate an active suppression of allergen skin test reactivity by active geohelminth infections [23].

Previous anthelmintic treatment studies have documented the effects of between 12 and 30 months of periodic treatments and have provided conflicting findings: (1) a non-randomized intervention study in Venezuela showed that monthly anthelmintic treatment with oxantel-pyrantel over 18 months increased the prevalence of allergen skin test reactivity to HDM from 17% to 68% among 94 children with a high prevalence of infection before treatment [10]; (2) an open-label placebo-controlled randomized intervention study in Gabon treated 165 children with a combination of praziquantel and mebendazole every 3 months for 30 months and showed that anthelmintic treatment increased the rate of developing skin sensitivity to HDM compared with the placebo (hazard ratio 2.51, 95% CI 1.85–3.41) among skin-test-negative children and the effect appeared to be mediated partly by reductions in infections with A. lumbricoides and T. trichiura [11]; (3) a double-blind randomized controlled trial in Vietnam treated 1566 schoolchildren in a hookworm-endemic region to receive placebo or mebendazole/albendazole at 3-monthly intervals and showed no effect of the intervention on clinical allergy but evidence of an increased prevalence of allergen skin test reactivity (OR 1.31, 95% CI 1.02–1.67) [12] and (4) a cluster-randomized study in Ecuador that allocated schools to monthly treatments with albendazole or no treatment showed no effect of treatment on allergen skin test reactivity or clinical allergy after 12 months of follow-up of 68 schools (1632 children) [13].

Possible explanations for differences in the effects of anthelmintic treatment on allergen skin test reactivity between studies are: (1) difference in treatment period – the treatment period was much longer in the present study (15–17 years) compared with the previous negative Ecuadorian study (1 year). Periodic anthelmintic treatment given over 15–17 years may cut transmission levels, reduce the prevalence of active infections, and attenuate the development of immune regulatory mechanisms associated with chronic infection. The mechanisms by which chronic geohelminth infections modulate allergen skin test reactivity are unclear. Enhanced production of IL-10 by lymphocytes stimulated with parasite antigen has been associated with reduced skin test responses in children infected with schistosomiasis [24], but not geohelminth infections [12, 25, 26]. (2) Differences in anthelmintic drugs – there is no evidence that any of the drugs used in the intervention studies (albendazole, mebendazole, praziquantel, oxantel-pyrantel and ivermectin) have direct effects on allergic reactivity but they do have differing spectrums of activity against geohelminth parasites [27]. Albendazole given at single doses of 400 mg is extremely effective against A. lumbricoides but has limited effects on T. trichiura infection [27]. In the present study, long-term ivermectin had no effect on A. lumbricoides prevalence, but had a significant impact on T. trichiura prevalence (treated 31.2% vs. untreated 81.5%). These findings are consistent with those of previous studies of the anthelmintic effects of one to four doses of ivermectin [28–30]. (3) Differences in endemic geohelminths – the type of geohelminth parasites endemic in a particular geographic region may be an important determinant of findings from different studies [10–13]. The prevalence of A. lumbricoides (55.9%) was similar in the present study to the previous negative Ecuadorian study [13], although infection intensities were greater in the previous study (GM infection intensity 73 epg) [13]. The prevalence and infection intensities of T. trichiura were lower in the previous study (prevalence 55.8%, GM infection intensity 25 epg) [13] compared with untreated children in the present study, and hierarchical analyses
indicated that the effect of anthelmintic treatment on SPT+ prevalence was mediated partly by this infection. A cohort study in urban Salvador in Brazil showed that infections, particularly high-intensity infections with *T. trichiura* during the first 3 years of life was associated with suppression of allergen skin test reactivity later in childhood and this effect was independent of later *T. trichiura* infections [8]. Thus, an explanation for the effect observed of *T. trichiura* infection in the present study may be the effect of treatment in reducing the prevalence of *T. trichiura* in early childhood, through a reduction in community transmission of infection. Such early effects could attenuate the development of immune regulatory mechanisms associated with chronic infection [31].

The effect of long-term ivermectin treatments on recent eczema symptoms was surprising, and was not associated with geohelminth infections in schoolchildren. There are four possible explanations for this observation: (1) data on eczema symptoms obtained by questionnaire may over-estimate prevalence where pruritic infections such as scabies are common. However, because ivermectin is an extremely effective treatment for scabies [15], the prevalence of scabies would be expected to be much higher among non-treated than treated children and is, therefore, an unlikely explanation for the greater prevalence of recent eczema symptoms observed among treated children. In fact, childhood infections with ectoparasites such as scabies and lice (against which ivermectin is also highly effective [32]), which were ubiquitous before the start of ivermectin and are now less common (EOEP, unpublished data) in treated communities; (2) an increased prevalence of recent eczema symptoms among children living in treated communities could be caused by impaired regulation of skin inflammation arising from the absence of regulatory effects in the skin that could be induced by scabies and lice; (3) effects of anthelmintic treatment on reducing maternal or early infant geohelminth infections – a previous intervention study has provided some evidence that long-term anthelmintic treatments – in this case 15–17 years, to our knowledge by far the longest period of continuous treatment so far documented through a real world public health intervention with high rates of treatment coverage sustained over many years [14] – may be associated with an increase in the prevalence of allergen skin test reactivity and possibly also recent eczema symptoms. The increase in allergen skin test reactivity, but not eczema symptoms, was associated with a reduced prevalence of *T. trichiura* infection.

**Acknowledgements**

We thank Dr Eduardo Gomez, Director, and members of the EOEP for their logistic support. We thank also the study communities for their enthusiastic participation. The study was funded by the Wellcome Trust (grant number 072405/Z/03/Z).

**References**

1. Nicolau N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. *Allergy* 2005; 60:1357–60.
2. Addo-Yobo EO, Woodcock A, Alloyet A, Baffoe-Bonnie B, Strachan D, Custovic A. Exercise-induced bronchospasm and atopy in Ghana: two surveys ten years apart. *PLoS Med* 2007; 4:e70.
3. Bethony J, Brooker S, Albonico M et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. *Lancet* 2006; 367:1521–32.
4. WHO. *Deworming for health and development: report of the Third Global Meeting of the Partners for Parasite Control*. Geneva: World Health Organization, 2005.
5. Davey G, Venn A, Belete H, Berhane Y, Britton J, Wheeze, allergic sensitization and geohelminth infection in Butajira, Ethiopia. *Clin Exp Allergy* 2005; 35:301–7.
6. Cooper PJ, Chico ME, Rodrigues LC et al. Reduced risk of atopy among school-age children infected with geohelminth parasites in a rural area of the tropics. *J Allergy Clin Immunol* 2003; 111:995–1000.
7. Flohr C, Tuyen LN, Lewis S et al. Poor sanitation and helminth infection protect against skin sensitization in Vietnamese children: a cross-sectional study. *J Allergy Clin Immunol* 2006; 118:1305–11.
8. Rodrigues LC, Newcombe PJ, SCAALA (Social Change, Asthma and Allergy in Latin America). *et al.* Early infection with
Anthelmintics increase allergen skin test reactivity

1677

Trichuris trichiura and allergen skin test reactivity in later childhood. Clin Exp Allergy 2008; 38:1769–77.

9 Scrivenor S, Yemaneberhan H, Zebenigus M et al. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case control study. Lancet 2001; 358:1493–9.

10 Lynch NR, Hagel I, Perez M, Di Prisco MC, Lopez R, Alvarez N. Effect of anthelmintic treatment on the allergic reactivity of children in a tropical slum. J Allergy Clin Immunol 1993; 92:404–11.

11 van den Biggelaar AH, Rodrigues LC, van Ree R et al. Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis 2004; 189:892–900.

12 Flohr C, Tuyen LN, Quin nell RJ et al. Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. Clin Exp Allergy 2010; 40:131–42.

13 Cooper PJ, Chico ME, Vaca MG et al. Effect of albendazole treatments on the prevalence of atopy in children living in communities endemic for geohelminth parasites: a cluster-randomised trial. Lancet 2006; 367:598–603.

14 Vieira JC, Cooper PJ, Lovato R et al. Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection. BMC Med 2007; 5:9.

15 Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrob Chemother 1994; 34:195–203.

16 Cooper PJ, Chico ME, Vaca MG et al. Risk factors for asthma and aller gy associated with urban migration: background and methodology of a cross-sectional study in Afro-Ecuadorian school children in Northeastern Ecuador (Esmeraldas-SCAALA Study). BMC Pulm Med 2006; 6:24.

17 Guderian RH, Shelley AJ. Onchocerciasis in Ecuador: the situation in 1989. Mem Inst Oswaldo Cruz 1992; 87:405–15.

18 Guderian RH, Mackenzie CD, Proaño JR. Onchocerciasis in Ecuador: absence of microfilaraemia. J Trop Med Hyg 1987; 90:213–4.

19 WHO. Diagnostic techniques for intestinal parasitic infections (IPI) applicable to primary health care (PHC) services. Geneva: WHO, 1985.

20 Cooper PJ, Rodrigues LC, Cruz AA, Barreto M. The asthma epidemic in Latin America: a public health challenge and research opportunities. Allergy 2009; 64:5–17.

21 von Mutius E. Asthma and allergies in rural areas of Europe. Proc Am Thorac Soc 2007; 4:212–6.

22 Elliott AM, Mpairwe H, Quigley MA et al. Helminth infection during pregnancy and development of infantile eczema. JAMA 2005; 294:2032–4.

23 Cooper PJ, Chico ME, Bland M, Griffin GE, Nutman TB. Allergic symptoms, atopy, and geohelminth infections in a rural area of Ecuador. Am J Respir Crit Care Med 2003; 168:313–7.

24 van den Biggelaar AH, van Ree R, Rodrigues LC et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 2000; 356:1723–7.

25 Cooper PJ, Mire E, Moncayo AL, Chico ME, Vaca M, Nutman TB. Ascaris lumbricoides-induced interleukin-10 is not associated with atopy in school children in a rural area of the tropics. J Infect Dis 2008; 197:1333–40.

26 Ponte EV, Lima F, Araújo MI, Oliveira RR, Cardoso LS, Cruz AA. Skin test reactivity and Der p-induced interleukin 10 production in patients with asthma or rhinitis infected with Ascaris. Ann Allergy Asthma Immunol 2006; 96:713–8.

27 Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008; 299:1937–48.

28 Raneque S, Chippaux JP, Garcia A, Boussinesq M. Follow-up of Ascaris lumbricoides and Trichuris trichiura infections in children living in a community treated with ivermectin at 3-monthly intervals. Ann Trop Med Parasitol 2001; 95:389–93.

29 Belizario VY, Amarillo ME, de Leon WI, de los Reyes AE, Bugayong MG, Macatangay BJ. A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 2003; 81:35–42.

30 Beach MJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am J Trop Med Hyg 1999; 60:479–86.

31 Cooper PJ, Barreto ML, Rodrigues LC. Human allergy and geohelminth infections: a review of the literature and a proposed conceptual model to guide the investigation of possible causal associations. Br Med Bull 2006; 79–80:203–18.

32 Pilger D, Heukelbach J, Khakban A, Araujo Oliveira F, Fengler G, Feldmeier H. Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial. Bull WHO 2010; 88:90–6.

33 Cooper PJ, Nutman TB. Onchocerciasis. In: Strickland GT, ed. Hunter’s tropical medicine, 8th Edn. Philadelphia: W. B. Saunders Co., 2000; 756–69.